We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM), which inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM), prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. It shows neuroprotective effect.
CAT No: R0975
CAS No: 676657-00-4
Synonyms/Alias: 676657-00-4;KYL peptide;L-Leucine,L-lysyl-L-tyrosyl-L-leucyl-L-prolyl-L-tyrosyl-L-tryptophyl-L-prolyl-L-valyl-L-leucyl-L-seryl-L-seryl-;KYL (trifluoroacetate salt);KYL;KYL TFA;HY-P2264;AKOS025142078;DA-54717;CS-0120761;G15846;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C74H108N14O17 |
M.W/Mr. | 1465.7 |
Sequence | One Letter Code:KYLPYWPVLSSL Three Letter Code:H-Lys-Tyr-Leu-Pro-Tyr-Trp-Pro-Val-Leu-Ser-Ser-Leu-OH |
Labeling Target | EphA4 receptor tyrosine kinase |
Activity | Inhibitor |
InChI | InChI=1S/C74H108N14O17/c1-40(2)31-52(64(94)84-59(39-90)68(98)85-58(38-89)67(97)83-57(74(104)105)33-42(5)6)80-71(101)62(43(7)8)86-70(100)61-19-14-30-88(61)73(103)56(36-46-37-77-51-17-10-9-15-49(46)51)82-66(96)54(35-45-22-26-48(92)27-23-45)79-69(99)60-18-13-29-87(60)72(102)55(32-41(3)4)81-65(95)53(34-44-20-24-47(91)25-21-44)78-63(93)50(76)16-11-12-28-75/h9-10,15,17,20-27,37,40-43,50,52-62,77,89-92H,11-14,16,18-19,28-36,38-39,75-76H2,1-8H3,(H,78,93)(H,79,99)(H,80,101)(H,81,95)(H,82,96)(H,83,97)(H,84,94)(H,85,98)(H,86,100)(H,104,105)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m0/s1 |
InChI Key | FZNPYIAZMDBRLC-RKNDTPCJSA-N |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCCN)N |
References | KYL was also shown to prevent growth cone collapse in chicken retinal explants and dissociated cultures of rat cortical neurons, promote nerve regeneration and functional recovery in a rat model of spinal cord injury, and inhibit the adhesion of human T-cells to endothelial cells. Thus, KYL can target human, mouse, rat and chicken EphA4 and may be useful for promoting nerve regeneration after injury and modulating immune responses. Distinctive Binding of Three Antagonistic Peptides to the Ephrin-Binding Pocket of the EphA4 Receptor STI and KYL inhibitors prevented AβO-induced dendritic spine loss. Although the absence of EphA4 did not completely rescue the dendritic spine loss, EphA4-knockout neurons show a significant decrease in AβO-induced dendritic spine loss. Furthermore, protection was observed in mature neurons (with established synapses) transfected with either c-Abl shRNA or EphA4 shRNA. EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-β oligomers |
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com